| Identification | Back Directory | [Name]
Ethanol, 2-[[[2-methoxy-6-(2-methyl[1,1'-biphenyl]-3-yl)-3-pyridinyl]methyl]amino]- | [CAS]
2628506-54-5 | [Synonyms]
PD-1/PD-L1-IN-9
Ethanol, 2-[[[2-methoxy-6-(2-methyl[1,1'-biphenyl]-3-yl)-3-pyridinyl]methyl]amino]- | [Molecular Formula]
C22H24N2O2 | [MOL File]
2628506-54-5.mol | [Molecular Weight]
348.44 |
| Chemical Properties | Back Directory | [Boiling point ]
498.5±45.0 °C(Predicted) | [density ]
1.127±0.06 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [solubility ]
DMSO : 100 mg/mL (286.99 mM; Need ultrasonic) | [form ]
Solid | [pka]
14.68±0.10(Predicted) | [color ]
White to off-white |
| Hazard Information | Back Directory | [Uses]
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model[1]. | [Biological Activity]
PD-1/PD-L1-IN-9 is a potent and orally active inhibitor of PD-1/PD-L1 interaction, with an IC50 of 3.8 nM. PD-1/PD-L1-IN-9 can enhance the killing activity of tumor cells by immune cells. PD-1/PD-L1-IN-9 also exhibits significant in vivo antitumor activity in a CT26 mouse model[1].
PD-1/PD-L1-IN-9 (compound 24) (46.9-1500 nM; pretreated for 2 h) dose-dependently significantly activates the antitumor immunity of PBMCs to MDB-MB 231 cells, with an EC50 of ～100 nM[1].
PD-1/PD-L1-IN-9 (compound 24) (40-80 mg/kg; p.o. once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice[1].PD-1/PD-L1-IN-9 (3 mg/kg; a single i.v.) exhibits half-life (t1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats[1].PD-1/PD-L1-IN-9 (25 mg/kg; a single p.o.) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1]. | [in vivo]
PD-1/PD-L1-IN-9 (compound 24) (40-80 mg/kg; p.o.; once a day for 2 weeks) inhibits tumor growth in a dose-dependent manner and does not cause any body weight loss or mortality of mice[1].
PD-1/PD-L1-IN-9 (3 mg/kg; i.v.; single dose) exhibits half-life (T1/2=4.2 h), plasma clearance (Cl=11.5 L/h/kg) and Cmax (1233 ng/mL) in rats[1].
PD-1/PD-L1-IN-9 (25 mg/kg; p.o.; single dose) exhibits moderate oral bioavailability (F=22 %), half-life (t1/2=6.4 h) and Cmax (192 ng/mL) in rats[1]. | Animal Model: | Male BALB/c mice (5-6 weeks) were inoculated CT26 cells[1] | | Dosage: | 40 mg/kg, 80 mg/kg | | Administration: | Oral gavage; once daily, for 2 weeks | | Result: | Significantly decreased the final tumor weight, with TGI values of 60 and 67% at the dose of 40 and 80 mg/kg, respectively. |
| Animal Model: | Pharmacokinetic analysis in sprague-Dawley (SD) rats[1] | | Dosage: | 3 mg/kg and 25 mg/kg | | Administration: | Intravenous injection or oral gavage; single dose | | Result: | | Route | Dose (mg/kg) | AUC(0-t) (ng·h/mL) | Cmax (ng/mL) | t1/2 (h) | Tmax | Cl (L·h/kg) | Vz (L/kg) | F (%) | | i.v. | 3 | 430.5 | 1233 | 4.2 | 0.03 | 11.5 | 78.6 | / | | p.o. | 25 | 787.4 | 192 | 6.4 | 0.69 | 28.8 | 249.3 | 22 |
|
| [References]
[1]. Wang T, et, al. Novel Biphenyl Pyridines as Potent Small-Molecule Inhibitors Targeting the Programmed Cell Death-1/Programmed Cell Death-Ligand 1 Interaction. J Med Chem. 2021 May 30. |
|
|